M&A / Deals Blackstone closes $6.3B fund for life sciences investing BioPharma DiveIt's the biggest life sciences private fund ever raised, coming in nearly 40% larger than its Blackstone predecessor vehicle.M&A / DealsRead full story pharminent March 30, 2026 (Last updated: March 31, 2026) BioPharma Dive It’s the biggest life sciences private fund ever raised, coming in nearly 40% larger than its Blackstone predecessor vehicle. M&A / DealsRead full story Post navigation Previous: Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 ReadoutNext: S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
